CSIMarket
 
Charles River Laboratories International inc   (NYSE: CRL)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $288.2400 $-3.26 -1.118%
Day's High: $291.4049987792969 Week Perf: -3.16 %
Day's Low: $ 284.34 30 Day Perf: 23.97 %
Volume (M): 1,086,021 52 Wk High: $ 303.31
Volume (M$): $ 0 52 Wk Avg: $191.72
Open: $285.91 52 Wk Low: $144.26



 Market Capitalization (Millions $) 14,110
 Shares Outstanding (Millions) 49
 Employees 19,700
 Revenues (TTM) (Millions $) 4,027
 Net Income (TTM) (Millions $) -183
 Cash Flow (TTM) (Millions $) -34
 Capital Exp. (TTM) (Millions $) 216

Business Description


Charles River Laboratories International, Inc. is a leading provider of research and preclinical services to help biotechnology, pharmaceutical, and other life sciences companies bring their products to market. The company is headquartered in Wilmington, Massachusetts and has more than 100 facilities around the world. Charles River Laboratories operates in three main business segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Support.

The Research Models and Services segment provides laboratory animal models and associated services to help researchers understand disease and test new drugs. The company offers a range of products including mice, rats, guinea pigs, hamsters, and nonhuman primates. Additionally, Charles River Laboratories provides model creation and breeding, barrier and containment facilities, and research support services.

The Discovery and Safety Assessment segment offers preclinical research and safety assessment services to pharmaceutical and biotechnology companies. The company conducts studies to evaluate the safety and efficacy of potential new drugs, including toxicology studies and safety pharmacology studies. Charles River Laboratories also provides high-throughput screening services, in vitro ADME/DMPK services, and in vivo pharmacology and efficacy services.

The Manufacturing Support segment provides biologics testing services and support through end-to-end solutions to help customers get their products to market quickly and efficiently. The company offers a wide range of services including cGMP manufacturing support, viral clearance studies, and regulatory support services.

Through a combination of its diverse service offerings and global presence, Charles River Laboratories has become a trusted partner for many large and small biotechnology and pharmaceutical companies. The company is committed to making significant contributions to the development of new drugs and therapies that will help save and improve lives.


   Company Address: 251 Ballardvale Street Wilmington 1887 MA
   Company Phone Number: 222-6000   Stock Exchange / Ticker: NYSE CRL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IQV        0.37% 
LH   -1.97%    
MEDP   -4.2%    
NOTV      0% 
OABI   -7.01%    
CYRX   -2.08%    
• View Complete Report
   



Business Update

Charles River Laboratories and Akron Bio Collaborate to Integrate CGMP Cytokines into Cell Therapy Platform,

Published Thu, Jan 16 2025 4:13 PM UTC

Charles River and Akron Bio Collaborate to Integrate CGMP Cytokines into Cell Therapy Platform WILMINGTON, Mass. In a strategic move to enhance operational capabilities and address the growing demands of the cell therapy sector, Charles River Laboratories International, Inc. (NYSE: CRL) has announced a collaboration with Akron Bio, a leading supplier of critical material...

Stocks on the Move

Charles River Laboratories Slumps Analyzing the Behind-the-Scenes Market Performance

Published Thu, Aug 8 2024 4:30 PM UTC

In recent weeks, Charles River Laboratories International Inc. s (CRL) stock has been struggling significantly, trailing behind the overall market performance. Several key factors are contributing to this slip, particularly related to recent earnings reports, shifts in investor sentiment, and broader market trends.For instance, a recent piece of analysis from Ariel Investmen...

Stocks on the Move

In an era where financial markets are increasingly intertwined with technological advancements and health solutions, significant movements within sectors warrant a dee...

Published Wed, Jul 31 2024 9:00 AM UTC

Revolutionizing Industries: Stock Strategies and Health Solutions Intersect in a Changing Market Landscape In an era where financial markets are increasingly intertwined with technological advancements and health solutions, significant movements within sectors warrant a deeper examination of their implications for investors and consumers alike. Recent developments concerning...

Business Update

Charles River Labs and AAVantgarde Announce Partnership for Plasmid DNA Manufacturing

Published Mon, Jul 8 2024 12:47 PM UTC

WILMINGTON, Mass. In a significant move for the biotechnology field, Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde have entered into a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) grade plasmid DNA.Charles River Laboratories, a renowned provider of essential products and serv...

Stocks on the Move

iShares iBoxx $ Investment Grade Corporate Bond ETF Sees Significant Short Interest Change

Published Wed, Jun 26 2024 10:49 AM UTC

In recent news, the iShares iBoxx $ Investment Grade Corporate Bond ETF has witnessed a notable shift in its short interest. Short interest refers to the total number of shares of a security that have been sold short and not yet repurchased. The change in short interest percentage from the previous report to the most recent report signifies a potential market sentiment shift...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.50
Price to Sales (Expected) -
Price to Book 4.79
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.21
Working Capital Ratio 1.66
Leverage Ratio (MRQ) 1.62
Total Debt to Equity 0.9
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.08

Per Share Current
Earnings (TTM) -3.72 $
Revenues (TTM) 82.27 $
Cash Flow (TTM) -
Cash 3.92 $
Book Value 60.19 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 204,418
Net Income per Employee (TTM) -9,281
Receivable Turnover Ratio (TTM) 5.53
Inventory Turnover Ratio (TTM) 7.56
Asset Turnover Ratio (TTM) 0.53

Profitability Ratios Current
Gross Margin (MRQ) 38.85 %
Operating Margin (MRQ) 12.04 %
Net Margin (MRQ) -1.49 %
Net Cash Flow Margin (MRQ) -1.79 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Charles River Laboratories International Inc's Segments
RMS    20.92 % of total Revenue
RMS Services and products transferred over time    9.46 % of total Revenue
RMS Services and products transferred at a point in time    11.46 % of total Revenue
DSA    59.94 % of total Revenue
DSA Services and products transferred over time    59.87 % of total Revenue
DSA Services and products transferred at a point in time    0.07 % of total Revenue
Manufacturing    19.13 % of total Revenue
Manufacturing Services and products transferred over time    9.13 % of total Revenue
Manufacturing Services and products transferred at a point in time    10.01 % of total Revenue
U S    54.61 % of total Revenue
Europe    27.87 % of total Revenue
Canada    11 % of total Revenue
Asia Pacific    5.57 % of total Revenue
Other    0.94 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.